Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

ABL Bio Financials and Metrics

Summary Metrics

Founding Date

2016

ABL Bio total Funding

$90.8 m

ABL Bio latest funding size

$65 m

Time since last funding

4 years ago

ABL Bio investors

ABL Bio's latest funding round in June 2018 was reported to be $65 m. In total, ABL Bio has raised $90.8 m
Show all financial metrics

ABL Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

ABL Bio Online and Social Media Presence

Embed Graph

ABL Bio News and Updates

Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among Others

Dublin, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc....

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South...

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bis…

ABL Bio Frequently Asked Questions

  • When was ABL Bio founded?

    ABL Bio was founded in 2016.

  • How many employees does ABL Bio have?

    ABL Bio has 33 employees.

  • Who are ABL Bio competitors?

    Competitors of ABL Bio include Courier Therapeutics, ImmVira and Precision Medicines.